Boehringer launches phase I/IIa of anti-SARS-CoV-2 antibody

Boehringer launches phase I/IIa of anti-SARS-CoV-2 antibody

The biopharma company, Boehringer Ingelheim, have initiated phase I/IIa clinical investigation of novel SARS-CoV-2 neutralising antibody, BI 767551. The study aims to provide the innovative SARS-CoV-2 neutralising antibody by combining a systemic with an inhaled route of administration.

The pre-clinical studies of BI 767551 (DZIF-10c) have demonstrated promising virus neutralising properties, said the company. The new phase I/IIa studies will analyse the safety, pharmacokinetics and antiviral activity of the antibody.

In phase I part of the study, participants will be given a single infusion or a single inhalation of the antibody. Late-stage confirmatory studies will be conducted if BI 767551 is observed to be well tolerated.The trial is conducted in association with Cologne University Hospital (UKK), University of Marburg (UMR) and the German Center for Infection Research (DZIF). The study will be led by UKK professors Florian Klein and Gerd Fätkenheuer, using the antibody supplied by the Boehringer Ingelheim.

“Monoclonal antibodies are a promising component in the fight against new viruses, such as the SARS-CoV-2. If this antibody turns out to be effective against COVID-19, this finding could be helpful in the current and also in future epidemics and pandemics.” said the University of Marburg Institute of Virology Director and DZIF Emerging Infections coordinator, Prof Stephan Becker.